Whoops: CMS quietly pares back list of drugs requiring new rebates under Inflation Reduction Act
To discourage rapid drug price increases, the Inflation Reduction Act requires pharma companies that raise certain drug prices faster than the rate of inflation to pay Medicare new rebates, beginning in 2025.
But the initial list of 27 drugs that would be hit with the rebates, unveiled March 15, was cut by about 25% late last week, with CMS now removing seven of those drugs, including two from Gilead.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.